ConductScience.org, home

Comparison · NCT02463799-deaths

Sipuleucel-T and Radium 223 Combination vs Sipuleucel-T Alone: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Sipuleucel-T and Radium 223 Combination vs Sipuleucel-T Alone: deaths from any cause. Trial comparisons, record NCT02463799-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02463799-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.194wilson
Risk in group 2000.194wilson
Risk difference, group 1 minus group 20-0.1940.194newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Sipuleucel-T and Radium 223 Combination
Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20~Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10~Radium-223: 6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223~Sipuleucel-T: 3 infusions of sipuleucel-T alone
016EG000
Group 2Sipuleucel-T AloneSipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10~Sipuleucel-T: 3 infusions of sipuleucel-T alone016EG001

Harm

What it counts
Total, all-cause mortality
Time frame
1 year

Source ClinicalTrials.gov

Trial

Title
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
NCT number
NCT02463799
Phases
PHASE2
Conditions
Prostate Cancer
Interventions
Radium-223, Sipuleucel-T
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Results first posted
2021-07-08

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02463799-deaths